Results 161 to 170 of about 39,319 (333)

PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma

Cancer Science, EarlyView.
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara, Isao Yoshida, Takuro Ishiguro, Katsuya Fujimoto, Junya Kuroda, Toshiki Uchida, Ryusuke Yamamoto, Yoshiaki Ogawa, Yasushi Hiramatsu, Toshiro Ito, Seiichiro Katagiri, Tomonori Nakazato, Kazumi Suzukawa, Kenzo Kinami, Mi Zhou, Eiju Negoro   +15 more
wiley   +1 more source

Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance

Journal of Advanced Research
Introduction: Patients with mantle cell lymphoma (MCL) frequently develop resistance to ibrutinib. Lymphoma-associated macrophages (LAMs) may play a causal role in this resistance but remain underexplored in current literature.
Xiaoqing Sun, Caiqin Wang, Jianghua Cao, Jing Li, Gang Ma, Xianqiu Wu, Peng Sun, Yu Wang, Jiajia Huang, Robert Peter Gale, Zhiming Li   +10 more
doaj  

BTK inhibitor ibrutinib in CLL and mantle cell lymphoma [PDF]

, 2013
Jame Abraham, Matt Stenger
openalex   +1 more source

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Journal of Clinical Oncology, 2017
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib.
C. Turtle, K. Hay, L. Hanafi, Daniel H. Li, S. Cherian, Xueyan Chen, B. Wood, A. Lozanski, J. Byrd, S. Heimfeld, S. Riddell, D. Maloney   +11 more
semanticscholar   +1 more source

Hypoxia Inhibitor Improves Iodine Uptake Disorder in Thyroid Cancer Through the hsa_circ_0023990/miR‐448/DNMT1/NIS Axis

Cancer Science, EarlyView.
Our study reveals that hypoxia inhibitors ameliorate iodine uptake dysfunction in thyroid cancer by acting on the hsa_circ_0023990/miR‐448/DNMT1/NIS signaling pathway. ABSTRACT This research seeks to investigate how hypoxia inhibitors enhance iodine uptake in thyroid cancer cells. Clinical samples were gathered and assessed for hsa_circ_0023990, DNMT1,
Ruiqin Gou, Shiqi Chen, Yangyang Lei, Pengqing Wu, Xuezhong Chen, Qing Zhang   +5 more
wiley   +1 more source

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

New England Journal of Medicine, 2013
BACKGROUND Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's
Michael L. Wang, S. Rule, P. Martin, A. Goy, R. Auer, B. Kahl, W. Jurczak, R. Advani, J. Romaguera, Michael E. Williams, J. Barrientos, E. Chmielowska, J. Radford, S. Stilgenbauer, M. Dreyling, W. Jędrzejczak, Peter W M Johnson, S. Spurgeon, Lei Li, L. Zhang, K. Newberry, Zhishuo Ou, N. Cheng, B. Fang, J. Mcgreivy, F. Clow, J. Buggy, B. Chang, D. Beaupre, L. Kunkel, K. Blum   +30 more
semanticscholar   +1 more source

Selinexor Reduces the Immunosuppression of Macrophages and Synergizes With CD19 CAR‐T Cells Against B‐Cell Lymphoma

Cancer Science, EarlyView.
In the tumor microenvironment, selinexor suppresses tumor cell growth and prevents macrophages from polarizing to M2 populations. The lower concentration of selinexor decreases CAR‐T cell exhaustion, enhances its cytotoxicity, and upregulates NGFR expression to prompt CAR‐T cell proliferation.
Wenjing Luo, Jia Xu, Chenggong Li, Lu Tang, Yingying Li, Xindi Wang, Zhuolin Wu, Yinqiang Zhang, Heng Mei, Yu Hu   +9 more
wiley   +1 more source

Ibrutinib Resistance in Chronic Lymphocytic Leukemia [PDF]

, 2014
Gustaaf Reurink, Gert Jan Goudswaard, Maarten H. Moen, Adam Weir, Jan A.N. Verhaar, Marco Sita, Mario Maas, Johannes L. Tol   +7 more
openalex   +1 more source

Mechanistic Insights and Therapeutic Potentials of Ubiquitin‐Proteasome System in Non‐Small Cell Lung Cancer

Cell Proliferation, EarlyView.
Lung cancer development involves mechanisms like reduced EGFR/EGF ubiquitination driving cancer cell behaviors and immune evasion via loss of PD‐1/PD‐L1 ubiquitination. Balancing ubiquitination and deubiquitination may be a potential therapeutic strategy. ABSTRACT Non‐small cell lung cancer (NSCLC) remains a leading cause of cancer mortality.
Guangyao Zhou, Jiaxiong Tan, Pengpeng Zhang, Zhaokai Zhou, Lianmin Zhang, Zhenfa Zhang   +5 more
wiley   +1 more source

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source